Kamada Reports Strong Q1 2025 Growth with 17% Revenue Increase and 54% EBITDA Surge
TL;DR
Kamada Ltd. reports a 17% revenue increase and 54% Adjusted EBITDA growth in Q1 2025, positioning it for organic growth and strategic acquisitions.
Kamada's Q1 2025 revenue reached $44.0 million, driven by GLASSIA and KAMRAB sales, with gross margins up to 47% from 44% year-over-year.
Kamada's advancements in treatments for AAT deficiency and rabies prevention, alongside plasma collection expansion, enhance global healthcare accessibility and disease management.
Kamada launches a CMV research program and opens a new plasma center, aiming to innovate in disease prevention and treatment strategies.
Found this article helpful?
Share it with your network and spread the knowledge!
Kamada Ltd. (NASDAQ: KMDA) has announced a robust start to 2025, with first-quarter revenue climbing 17% to $44.0 million and Adjusted EBITDA soaring 54% to $11.6 million compared to the same period last year. This performance underscores the company's ability to sustain growth through a diversified product portfolio and operational efficiency. Key contributors to this growth include GLASSIA® and KAMRAB® in non-U.S. markets, alongside sales of VARIZIG® and royalty income from GLASSIA.
The company's strategic initiatives, including the expansion of its plasma collection operations with a new center in San Antonio, Texas, and a significant contract to supply KAMRAB and VARIZIG in Latin America, highlight Kamada's commitment to reducing dependency on third-party suppliers and enhancing its market presence. The new plasma center is expected to contribute $8 million to $10 million in annual revenue at full capacity, while the Latin American deal is projected to generate approximately $25 million over three years.
Kamada's focus on innovation is evident in its post-marketing research program for CYTOGAM®, aimed at advancing CMV disease management, and the ongoing InnovAATe clinical trial for its inhaled Alpha-1 Antitrypsin therapy. These efforts, coupled with the company's reiterated guidance for 2025—anticipating total revenue between $178 million and $182 million and adjusted EBITDA of $38 million to $42 million—reflect confidence in sustained growth and profitability.
The implications of Kamada's Q1 achievements extend beyond financial metrics, signaling the company's potential to influence the global plasma-derived therapeutics market and improve treatment options for patients with rare and life-threatening conditions. As Kamada continues to execute its strategic growth pillars, including organic commercial expansion, business development, and plasma collection operations, its trajectory offers a compelling narrative for stakeholders in the healthcare and investment communities.
Curated from NewMediaWire
